- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This landscape analysis surveys the current state of technologies for the treatment of hepatitis C virus (HCV), as well as market dynamics that affect the affordability and accessibility of HCV therapeutics. HCV treatment falls within the ambit of UNITAID’s mission because it is a major HIV coinfection and a leading cause of morbidity and mortality among people living with HIV. Strategic Objective 3 of the UNITAID Strategy 2013−2016 specifically refers to viral hepatitis, notably hepatitis B and C.
Recent estimates report that only 54% of people with HIV know their HIV status. In order to reach the UN 90–90–90 goals it is critical that HIV testing services be strategically expanded to diagnose as many people with HIV as early as possible.
This fact sheet includes data on HIV testing services reported by countries to the Global AIDS Response Progress Reporting (GARPR) (WHO, UNAIDS, UNICEF) as of July 2015.
The Board is presenting this special report to Member States in the hope that the analysis and recommendations presented therein may assist them in the development of national policies and control systems that are capable of achieving the goals of the international drug control conventions in relation to ensuring availability of narcotic drugs and psychotropic substances. Member States have already underlined the importance of this issue in a number of resolutions and political declarations adopted by the Commission on Narcotic Drugs. They also referred to it in the Political Declaration of the High-Level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases and in resolution WHA67.19 of the World Health Assembly, on strengthening of palliative care as a component of comprehensive care throughout the life course.
Keywords: HIV/AIDS, law enforcement, medicines, drug
All babies have the right to a healthy start in life.
Every year, approximately 1.5 million HIV-positive women give birth. If they are unable to access medicine and services, they run the risk of transmitting HIV to their babies during pregnancy, delivery and the breastfeeding period.
Now, with only one pill a day started during pregnancy, along with delivery in a medical facility by a skilled health professional and continued treatment through the breastfeeding period, advances in antenatal care mean that the risk of HIV transmission from mother to baby can be virtually eliminated.
This document provides Cohort analysis for patients who started ART in 2013 (12 months), Cohort analysis for patients who started ART in 2012 (24 months) and Cohort analysis for patients who started ART in 2009 (60 months).
Keywords: ART, treatment, clinic, deaths
The purpose of this manual is to provide guidance to public health professionals tasked with managing a response to viral hepatitis. As every country’s needs are different with respect to its epidemiology and the current level of response, people would use this manual in different ways.
The HIV epidemic amongst men who have sex with men (MSM) in Bangkok is substantial. The population size of MSM in Bangkok is 120,000-250,000, with approximately one-third (33.5 percent) considered high-risk, characterized by their young age, multiple partnerships, frequent unprotected anal intercourse, and sexual activities around MSM hotspots. In metropolitan Bangkok, HIV prevalence among MSM reportedly increased from 21 percent to 28 percent between 2000 and 2012. The Thai Working Group of Estimation and Projection (2013) projected an estimate of 39,000 new HIV infections would occur in Thailand during 2012-2016, based on the AIDS Epidemic Model (AEM).
WHO guidelines on antiretroviral therapy (ART) have evolved during the past decade towards recommending earlier treatment, as evidence has shown clinical and public health benefit, treatment has become simpler, more tolerable and more affordable, and systems for ARV delivery have been streamlined for scale.
This update summarizes experiences of countries that have already begun to implement earlier treatment approaches as part of a national policy or pilot programmes. Overall, these five country examples demonstrate that scaling up a treat-all policy, across diverse populations (adults, key populations and children) is acceptable and feasible, with early benefits and no immediate evidence of harmful effects.
HIV treatment is a cornerstone of the AIDS response, helping to prevent AIDS-related deaths and avert new infections. It also helps people living with HIV to live close-to-normal lifespans, thereby reducing HIV-related stigma. Evidence shows that HIV treatment, administered ideally as soon as possible after diagnosis, not only slows disease progression but also prevents onward HIV transmission. Moreover, the right to the highest attainable standard of health necessitates access to treatment and other medicines to ensure that people living with HIV can have long and productive lives.
Keywords: HIV, treatment, human rights, Fast-Track, medicines, financing
The aim of the new initiative is to leverage improved, accessible, affordable and optimally used diagnostic technologies and strategies to ensure achievement of a bold new HIV treatment target for 2020.